Abacavir sulphate equivalet to abacavir, dolutegravir, lamivudine
Sold as Tulodiv
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Tulodiv Each Tablet contains: Abacavir Sulphate equivalet to Abacavir 600,0 mg; Dolutegravir Sodium equivalent to Dolutegravir 50,0 mg; Lamivudine 300,0 mg | 600 mg, 50 mg, 300 mg,Film-coated tablets | 57010857/20.2.8/0108Approved 17 June 2025 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Abacavir
Consolidated Schedules 06 July 2026, line 5118
S4: Dolutegravir
Consolidated Schedules 06 July 2026, line 6100
S4: Lamivudine
Consolidated Schedules 06 July 2026, line 6850
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.